The FDA has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis.

People with allergic fungal rhinosinusitis taking Dupixent (dupilumab) saw significant improvement in congestion and sinus ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients ...

The probability of revision sinus surgery including the removal of nasal polyps is higher if the patient has asthma or is on antibiotics at the time of their initial surgery. However, higher age was ...

Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis Approval in adults and children aged 6 years and older supported by phase 3 study ...

The FDA has approved dupilumab to treat allergic fungal rhinosinusitis in adults and children ages 6 years and older.

Subjective — but not objective — olfactory improvements in patients who underwent endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps were maintained up to 6 months after surgery, ...

Patients with chronic rhinosinusitis (CRS) with severe radiographic disease were more likely to report incidence of nasal polyps and be managed by endoscopic sinus surgery, but did not show greater ...

Dear Dr. Roach: I have suffered from asthma and nasal polyps for more than 20 years. The asthma is controlled, and I mention it only because it might have some connection with my polyps. The polyps ...

Women using estrogen-containing contraceptives vs. not using any systemic hormonal contraceptives had reduced odds for ...

LIBERTY-AFRS-AIMS met its primary endpoint with a 50% reduction in CT sinus opacification at week 52 versus 10% with placebo (P<.0001).